Skip to main
SCNI

SCNI Earnings Dates & Reports

SCNI Most Recent Earnings

Report Date
Period EndingQ2 2023
Est. EPS-$0.91
Actual EPS-$1.20
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

SCNI Earnings per Share (EPS) History

Signup for full access
Browse free

SCNI Latest Earnings

The value each SCNI share was expected to gain vs. the value each share gained.

SCNI reported its most recent earnings on for Q2 2023, posting earnings per share (EPS) of -$1.20. This exceeded analysts' expectations of -$0.91 by 31.87%, marking a Miss.

For comparison, Scinai Immunotherapeutics Ltd reported EPS of -$2 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.80.

SCNI Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2025
Q4 2024
-$9.57
DeckReportListen
Q3 2024
-$8.40
DeckReportListen
Q2 2024
-$4.00
DeckReportListen
Q1 2024
-$4.00
DeckReportListen
View all

SCNI Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Scinai Immunotherapeutics Ltd’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

SCNI Earnings FAQs

SCNI last reported earnings on Aug 11, 2023 for Q2 2023, posting an EPS of -$1.20, which Miss the estimate of -$0.91 by 31.87%.

For Q2 2023, SCNI reported an EPS of -$1.20, missing analysts' estimate of -$0.91 by 31.87%.

For Q2 2023, SCNI Miss expectations with an actual EPS of -$1.20 vs. an estimated EPS of -$0.91.

Following the last earnings report on Aug 11, 2023, SCNI's stock price moved — from — to —.

The next SCNI earnings call is scheduled for Jan. 6, 2026, where executives will discuss financial results and outlook.

Scinai Immunotherapeutics Ltd (SCNI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.